NASDAQ:KPTI • US48576U2050
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KARYOPHARM THERAPEUTICS INC (KPTI).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-27 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2026-03-30 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2026-03-25 | Baird | Maintains | Outperform -> Outperform |
| 2026-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-10 | Rodman & Renshaw | Initiate | Buy |
| 2026-02-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-05 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-11-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-13 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-10-09 | Baird | Maintains | Outperform -> Outperform |
| 2025-10-09 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-08-12 | Baird | Maintains | Outperform -> Outperform |
| 2025-07-16 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-05-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-13 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-03-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-02-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-20 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-02-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-10 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 146.033M -7.04% | 145.237M -0.55% | 146.067M 0.57% | 140.24M -3.99% | 171.6M 22.36% | 218.95M 27.59% | 359.44M 64.17% | 515.51M 43.42% | 655.09M 27.08% | 740.77M 13.08% | 537.95M -27.38% | |
| EBITDA YoY % growth | -129.01M 8.88% | -119.103M 7.68% | -90.411M 24.09% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -129.54M 8.90% | -119.443M 7.79% | -90.707M 24.06% | -99.585M -9.79% | -77.699M 21.98% | 83.699M 207.72% | 81.942M -2.10% | 249.02M 203.90% | 369.75M 48.48% | 445.82M 20.57% | 427.66M -4.07% | |
| Operating Margin | -88.71% | -82.24% | -62.10% | -71.01% | -45.28% | 38.23% | 22.80% | 48.31% | 56.44% | 60.18% | 79.50% | |
| EPS YoY % growth | -18.75 38.42% | -10.05 46.40% | -13.13 -30.65% | -4.54 65.42% | -3.66 19.31% | -1.23 66.45% | 0.99 180.50% | 2.32 134.02% | 3.47 49.78% | 4.13 19.12% | 4.67 13.09% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.46 47.40% | -1.21 72.07% | -1.02 73.34% | -1.05 52.74% | -1.51 -3.95% | -1.36 -12.44% | -1.17 -14.66% | -1.13 -7.43% |
| Revenue Q2Q % growth | 32.027M 6.70% | 35.48M -6.46% | 36.476M -17.18% | 36.256M 6.39% | 30.855M -3.66% | 35.802M 0.91% | 43.86M 20.24% | 46.767M 28.99% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -24.518M 26.27% | -22.746M 6.73% | -23.096M -51.75% | -24.96M -39.88% | -28.433M -15.96% | -20.677M 9.09% | -12.816M 44.51% | -9.609M 61.50% |
All data in USD
13 analysts have analysed KPTI and the average price target is 12.24 USD. This implies a price increase of 41.34% is expected in the next year compared to the current price of 8.66.
KARYOPHARM THERAPEUTICS INC (KPTI) will report earnings on 2026-04-30.
The consensus EPS estimate for the next earnings of KARYOPHARM THERAPEUTICS INC (KPTI) is -1.46 USD and the consensus revenue estimate is 32.03M USD.
The number of analysts covering KARYOPHARM THERAPEUTICS INC (KPTI) is 13.